filmov
tv
EMA Grants Orphan Status to NurExone (TSXV:NRX) ExoPTEN for Spinal Cord Injury
Показать описание
NurExone Biologic's ExoPTEN, a cutting-edge therapy for spinal cord injuries, has secured Orphan Drug Designation from the EMA. Discover how this breakthrough treatment aims to revolutionize nerve regeneration and recovery for patients worldwide.
0:03:55
EMA Grants Orphan Status to NurExone (TSXV:NRX) ExoPTEN for Spinal Cord Injury
0:07:53
Orphan Drug Development | Episode 06 - USFDA vs EMA : Orphan Drug Designation | Regulatory Affairs
0:03:18
What are Orphan Medicines? - Video explainer
3:34:55
COMP Workshop Support for development of orphan medicines
0:27:20
How to apply and benefit from an Orphan Drug Designation
0:03:27
FDA Incentives to Promote Rare Disease Drug Development
0:03:14
Neuroscience Advances: Stem Cell Therapies and Migraine Innovations
0:01:45
Orphan Drug, Rare Pediatric Disease, and Expedited Program Designations Webinar (10/6)
0:55:37
Orphan Drug & Rare Disease Development: Understanding the European and US Regulatory Landscape
0:08:42
HealthWealth Investor Toolkit: Beginner's Guide to understanding Regulatory Approval of Orphan ...
0:58:11
No Opportunity Unturned: Optimizing Orphan Drug Development
0:00:42
Key Considerations for Orphan Drug Designation
0:04:11
Rare Diseases Update by LucidQuest Episode 13
0:57:19
The European Medicines Agency and patient involvement in the drug approval process
0:05:34
Rare Diseases Update by LucidQuest Episode 16
0:27:14
2018 Symposium of HBio: Regulatory Path for orphan drugs
0:03:14
Neuroscience Advances: Stem Cell Therapies and Migraine Innovations
0:04:12
Rare Diseases Update by LucidQuest Episode 15
0:03:59
Rare Disease Advances: AI, Acquisitions, Approvals & More
0:01:31
Weekly Roundup - PHARMA - 25 November 2024
0:08:33
Orphan Drug Development | Episode 05 - How to get Orphan Drug Designation in USA | USFDA | DRA
0:16:11
Regulatory Shorts#8 | How to get Marketing Authorisation in European Union (EU)? | Drug Registration
0:00:50
CEL-SCI Corporation (CVM)
0:48:54
Taking Advantage of the Orphan Drug Act - Webinar
Комментарии